Ubiquitination modifications as central regulators of metabolic dysfunction in type 2 diabetes mellitus
-
By
-
Wen-tao Wang
-
Ze-ya Shi
-
Hai-long Wang
-
Zhao-yang Chen
-
July 9, 2026
-
Clinical Scorecard: The Role of Ubiquitination Modifications in Regulating Metabolic Dysfunction in Type 2 Diabetes Mellitus
At a Glance
| Category | Detail |
|---|
| Condition | Type 2 Diabetes Mellitus |
| Key Mechanisms | Ubiquitination and deubiquitination processes regulating protein stability and activity. |
| Target Population | Individuals with Type 2 Diabetes Mellitus. |
| Care Setting | Clinical research and metabolic disease management. |
Key Highlights
- Ubiquitination is a central regulator of cellular homeostasis in T2DM.
- E3 ubiquitin ligases and deubiquitinating enzymes (DUBs) play critical roles in insulin signaling.
- Dysregulation of ubiquitination contributes to insulin resistance and pancreatic β-cell dysfunction.
- Targeting the ubiquitination system may offer new therapeutic strategies for T2DM.
- Integration of multi-omics approaches and AI platforms is essential for future research.
Guideline-Based Recommendations
Diagnosis
- Monitor for insulin resistance and pancreatic β-cell dysfunction.
Management
- Consider targeting E3 ligases and DUBs for therapeutic interventions.
Monitoring & Follow-up
- Evaluate metabolic homeostasis across liver, skeletal muscle, and adipose tissue.
Risks
- Increased prevalence of T2DM linked to genetic, epigenetic, and environmental factors.
Patient & Prescribing Data
Adults aged 20–79 years with Type 2 Diabetes Mellitus.
Focus on precision therapies targeting the ubiquitination system.
Clinical Best Practices
- Utilize a multi-organ integration approach in understanding T2DM pathology.
- Adopt enzyme-specific resolution in research and treatment strategies.
Related Resources & Content
